Amicus Therapeutics Company Profile (NASDAQ:FOLD)

About Amicus Therapeutics

Amicus Therapeutics logoAmicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: FOLD
  • CUSIP: 03152W10
Key Metrics:
  • Previous Close: $7.80
  • 50 Day Moving Average: $7.06
  • 200 Day Moving Average: $6.95
  • 52-Week Range: $4.98 - $14.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.80
  • P/E Growth: -0.15
  • Market Cap: $1.11B
  • Outstanding Shares: 142,139,000
  • Beta: 1.67
Profitability:
  • Return on Equity: -50.69%
  • Return on Assets: -19.08%
Debt:
  • Current Ratio: 2.62%
  • Quick Ratio: 2.62%
Additional Links:
Companies Related to Amicus Therapeutics:

Analyst Ratings

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $12.88 (65.06% upside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
Show:
DateFirmActionRatingPrice TargetDetails
8/11/2016Chardan CapitalSet Price TargetBuy$15.00View Rating Details
6/14/2016Leerink SwannReiterated RatingOutperform$17.00 -> $19.00View Rating Details
5/18/2016Bank of America Corp.Initiated CoverageBuy$10.00View Rating Details
4/13/2016Robert W. BairdInitiated CoverageNeutral$9.00View Rating Details
3/30/2016Goldman Sachs Group Inc.Initiated CoverageNeutral$10.00View Rating Details
3/8/2016Janney Montgomery ScottUpgradeNeutral -> Buy$10.00 -> $12.00View Rating Details
3/7/2016Cowen and CompanyReiterated RatingOutperform$13.00View Rating Details
2/23/2016JPMorgan Chase & Co.Reiterated RatingBuy$18.00 -> $15.00View Rating Details
6/16/2015B. RileyBoost Price TargetBuy$14.00 -> $17.50View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Amicus Therapeutics (NASDAQ:FOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
8/9/2016Q2($0.33)($0.40)$0.17 millionViewN/AView Earnings Details
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details
2/26/2016Q4($0.31)($1.20)ViewListenView Earnings Details
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details
8/5/2015Q215($0.24)($0.27)ViewN/AView Earnings Details
5/5/2015Q115($0.21)($0.25)ViewN/AView Earnings Details
3/3/2015Q414($0.18)($0.24)ViewN/AView Earnings Details
11/6/2014($0.21)($0.22)ViewN/AView Earnings Details
8/7/2014($0.23)($0.31)ViewN/AView Earnings Details
5/5/2014($0.24)($0.25)ViewN/AView Earnings Details
3/3/2014Q4 13($0.32)($0.22)ViewN/AView Earnings Details
11/11/2013Q3($0.32)($0.29)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amicus Therapeutics (NASDAQ:FOLD)
Current Year EPS Consensus Estimate: $-1.35 EPS
Next Year EPS Consensus Estimate: $-1.00 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.31)($0.31)($0.31)
Q4 20161($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Amicus Therapeutics (NASDAQ:FOLD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Amicus Therapeutics (NASDAQ:FOLD)
Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 99.06%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2016William D Baird IIICFOSell20,500$8.00$164,000.00View SEC Filing  
9/6/2016Hung DoInsiderSell25,000$7.00$175,000.00View SEC Filing  
8/25/2016Perceptive Advisors LlcInsiderSell1,100,000$6.81$7,491,000.00View SEC Filing  
8/4/2016Jay BarthInsiderSell10,458$7.00$73,206.00View SEC Filing  
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.00View SEC Filing  
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.00View SEC Filing  
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.00View SEC Filing  
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78View SEC Filing  
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.08View SEC Filing  
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00View SEC Filing  
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.00View SEC Filing  
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Amicus Therapeutics (NASDAQ:FOLD)
DateHeadline
News IconAnalysts Valuations For Two Stocks: Cliffs Natural Resources Inc (NYSE:CLF), Amicus Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - September 27 at 5:03 PM
News IconTwo Biotechnology Names Are Hot: Navidea Biopharmaceuticals, Inc (NAVB), Amicus Therapeutics, Inc. (FOLD)c - The Independent Republic (NASDAQ:FOLD)
theindependentrepublic.com - September 27 at 5:03 PM
fool.com logo3 Biotechs With Potential Big-Time Upside (NASDAQ:FOLD)
www.fool.com - September 27 at 5:03 PM
4-traders.com logoAmicus Therapeutics : UPDATE -- Amicus Therapeutics to Present at Bank of America Merrill Lynch Global Healthcare Conference 2016 (NASDAQ:FOLD)
www.4-traders.com - September 26 at 5:13 PM
News IconStock in Spotlight: MFA Financial, Inc. (NYSE:MFA), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Newburgh Press (NASDAQ:FOLD)
newburghpress.com - September 26 at 9:48 AM
News IconIntraday Active Biotech Stocks News: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Amicus Therapeutics, Inc ... - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - September 26 at 9:48 AM
News IconLooking Ahead for Amicus Therapeutics, Inc. (NASDAQ:FOLD); Are These Shares Ready to Go Higher? - Frisco Fastball (NASDAQ:FOLD)
friscofastball.com - September 25 at 4:38 PM
seekingalpha.com logoAmicus Is A Winner - Seeking Alpha (NASDAQ:FOLD)
seekingalpha.com - September 24 at 9:40 AM
finance.yahoo.com logoAmicus Therapeutics to Present at LEERINK Roundtable Series: Rare Disease & Immuno-Oncology (NASDAQ:FOLD)
finance.yahoo.com - September 22 at 10:38 AM
nasdaq.com logoCommit To Buy Amicus Therapeutics At $5, Earn 15% Using Options - Nasdaq (NASDAQ:FOLD)
www.nasdaq.com - September 21 at 5:34 PM
News IconTrader's Focus- Amicus Therapeutics, Inc.'s (FOLD) - Hot Stocks Point - Hot Stocks Point (NASDAQ:FOLD)
www.hotstockspoint.com - September 21 at 5:34 PM
nasdaq.com logoCommit To Buy Amicus Therapeutics At $5, Earn 15% Using Options (NASDAQ:FOLD)
www.nasdaq.com - September 21 at 9:19 AM
News IconBiotech Stocks Worth Chasing: Opko Health, Inc. (OPK), Amicus Therapeutics, Inc. (FOLD) - The Independent Republic (NASDAQ:FOLD)
theindependentrepublic.com - September 19 at 4:01 PM
seekingalpha.com logoAmicus Therapeutics: Key Catalysts Approaching - Seeking Alpha (NASDAQ:FOLD)
seekingalpha.com - September 19 at 4:01 PM
nasdaq.com logoBullish Two Hundred Day Moving Average Cross - FOLD (NASDAQ:FOLD)
www.nasdaq.com - September 17 at 4:52 PM
nasdaq.com logoBullish Two Hundred Day Moving Average Cross - FOLD - NASDAQ ... - Nasdaq (NASDAQ:FOLD)
www.nasdaq.com - September 17 at 9:46 AM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD) Quarterly EPS Review - Newburgh Press (NASDAQ:FOLD)
newburghpress.com - September 17 at 9:46 AM
News IconTrading the Biotech News: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Dynavax Technologies Corporation (NASDAQ ... - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - September 17 at 9:46 AM
News IconUPDATE — Amicus Therapeutics to Present at Bank of America Merrill Lynch Global Healthcare Conference 2016 (NASDAQ:FOLD)
virtual-strategy.com - September 15 at 5:27 PM
News IconStocks Raising Investors Eye Brows: Geron Corporation (NASDAQ:GERN), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Wise Report (press release) (blog) (NASDAQ:FOLD)
streetwisereport.com - September 14 at 5:07 PM
News IconActive biotech company shares in the news: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Agios Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - September 12 at 9:54 AM
News IconHC Stocks in Focus= Arena Pharmaceuticals, Inc. (ARNA), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - share market updates (press release) (NASDAQ:FOLD)
sharemarketupdates.com - September 12 at 9:54 AM
finance.yahoo.com logoAmicus Therapeutics to Present at Bank of America Merrill Lynch Global Healthcare Conference 2016 (NASDAQ:FOLD)
finance.yahoo.com - September 12 at 9:54 AM
News IconAnalysts Speculate on Amicus Therapeutics, Inc. (NASDAQ:FOLD ... - Post Registrar (NASDAQ:FOLD)
postregistrar.com - September 9 at 4:54 PM
News IconBrokerage Firm Rating Update on ZIOPHARM Oncology Inc (ZIOP) (NASDAQ:FOLD)
thelakeandeswave.com - September 9 at 9:50 AM
nasdaq.com logoImplied IHE Analyst Target Price: $188 (NASDAQ:FOLD)
www.nasdaq.com - September 9 at 9:50 AM
News IconBuzzing Stocks of Biotechnology: ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Post Registrar (NASDAQ:FOLD)
postregistrar.com - September 7 at 5:14 PM
biz.yahoo.com logoAMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:FOLD)
biz.yahoo.com - September 7 at 5:14 PM
News IconHC Stocks Highlights- Amicus Therapeutics, Inc. (NASDAQ:FOLD ... - share market updates (press release) (NASDAQ:FOLD)
sharemarketupdates.com - September 7 at 8:23 AM
News IconAnalysts Valuations For Two Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD), ImmunoGen, Inc. (NASDAQ:IMGN) - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - September 7 at 8:23 AM
News IconAnalysts Valuations For Two Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Patterson-UTI Energy, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - September 2 at 4:59 PM
News IconAnalysts Valuations For Two Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Patterson-UTI Energy, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - September 2 at 4:59 PM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD) reported actual EPS of -0.4 in the last Quarter - Newburg Press (NASDAQ:FOLD)
newburghpress.com - September 1 at 4:57 PM
finance.yahoo.com logoAmicus Therapeutics to Present at Robert W. Baird & Co. 2016 Healthcare Conference (NASDAQ:FOLD)
finance.yahoo.com - September 1 at 4:57 PM
News IconAnalysts Valuations For Two Stocks: WisdomTree Investments, Inc. (NASDAQ:WETF), Amicus Therapeutics, Inc ... - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - August 31 at 5:38 PM
finance.yahoo.com logoAmicus Therapeutics to Highlight Fabry Disease Program at Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium (NASDAQ:FOLD)
finance.yahoo.com - August 31 at 9:49 AM
News IconBiotech Stocks Worth a Closer Look: Array BioPharma Inc. (NASDAQ:ARRY), Amicus Therapeutics, Inc. (NASDAQ:FOLD) - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - August 30 at 5:08 PM
News IconHow is the Crowd Rating Amicus Therapeutics, Inc. (NASDAQ:FOLD ... - Post News (NASDAQ:FOLD)
www.kentuckypostnews.com - August 30 at 8:10 AM
News IconHot Biotech Stocks Recap: ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC), Amicus Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - August 25 at 10:05 AM
News IconAmicus Therapeutics, Inc.'s (FOLD): Stock on the Move - Hot Stocks Point (NASDAQ:FOLD)
www.hotstockspoint.com - August 25 at 10:05 AM
biz.yahoo.com logoAMICUS THERAPEUTICS INC Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:FOLD)
biz.yahoo.com - August 23 at 5:13 PM
News IconTrader's Roundup: Thermo Fisher Scientific Inc (TMO), Amicus Therapeutics (FOLD) - Newburg Press (NASDAQ:FOLD)
newburghpress.com - August 22 at 5:05 PM
News IconAmicus Therapeutics, Inc.'s (FOLD): Stock in the Trader's Radar - Hot Stocks Point (NASDAQ:FOLD)
www.hotstockspoint.com - August 22 at 9:42 AM
News IconIntraday Active Biotech Stocks News: Amicus Therapeutics (NASDAQ:FOLD), PDL BioPharma (NASDAQ:PDLI) - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - August 22 at 9:42 AM
finance.yahoo.com logoAMICUS THERAPEUTICS INC Financials (NASDAQ:FOLD)
finance.yahoo.com - August 18 at 5:05 PM
News IconIntraday Active Biotech Stocks News: Illumina (NASDAQ:ILMN), Amicus Therapeutics (NASDAQ:FOLD) - The Voice Registrar (NASDAQ:FOLD)
voiceregistrar.com - August 17 at 10:22 PM
streetinsider.com logoAmicus Therapeutics (FOLD) Says Data From Phase 3 FACETS Study Published in NEJM (NASDAQ:FOLD)
www.streetinsider.com - August 11 at 5:18 PM
finance.yahoo.com logoRare disease drug innovation: Amicus CEO (NASDAQ:FOLD)
finance.yahoo.com - August 11 at 5:18 PM
thestreet.com logoAmicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines' (NASDAQ:FOLD)
www.thestreet.com - August 11 at 5:18 PM
finance.yahoo.com logoUPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease (NASDAQ:FOLD)
finance.yahoo.com - August 10 at 11:14 PM

Social

Amicus Therapeutics (NASDAQ:FOLD) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff